@article{JTD3105,
author = {Haidong Huang and Paul Zarogoulidis and Sofia Lampaki and John Organtzis and Dimitris Petridis and Konstantinos Porpodis and Antonis Papaiwannou and Vasilis Karageorgiou and Georgia Pitsiou and Ioannis Kioumis and Wolfgang Hohenforst-Schmidt and Qiang Li and Kaid Darwiche and Lutz Freitag and Aggeliki Rapti and Konstantinos Zarogoulidis},
title = {Experimentation with aerosol bonsetan, pirfenidone, treprostinil and sidenafil},
journal = {Journal of Thoracic Disease},
volume = {6},
number = {10},
year = {2014},
keywords = {},
abstract = {Introduction: Pulmonary hypertension (PH) has been identified either as a symptom or a primary entity. Several drugs are already on the market and other are being investigated. Idiopathic pulmonary fibrosis (IPF) is also a disease were several drugs are being investigated.
Materials and methods: Three jet nebulizers and three ultrasound nebulizers were used for our experiments with seven different residual cups and four different loadings. Bonsetan, treprostinil, sidenafil and pirfenidone were modified in order to be produced as aerosol in an effort to identify parameters which influence the droplet size production size.
Results: The four-way ANOVA on droplet size using the jet nebulizers revealed two statistically significant factors, drug (F=6.326, P=0.0007) and residual cup (F=4.419, P=0.0007), and their interaction term (F=5.829, P},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/3105}
}